The Long COVID Treatment Trial

Part of paid clinical trials in La Jolla, California.

Sponsor
Scripps Translational Science Institute
Study ID
NCT07128082
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tirzepatide — DRUG
    The treatment group will receive the study medication (tirzepatide) for a 12 month period starting with a 2.5mg dose once a week.
  • Placebo — DRUG
    Participants in the control group will receive a placebo instead of active study medication for a 12 month period.

Study Details

The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that has no medication. Participants will take the medication (or placebo) they are given and complete study surveys for 12 months. All of the study tasks are done remotely from the comfort of a participants home.

Key Dates

Start date
Oct 30, 2025
Status verified
Dec 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
1,000 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: 500 Participants will be randomized to receive placebo instead of active study medication.
  • Active Comparator: 500 Participants will be randomized to receive active study medication.

Primary Outcome Measure

Primary Objective 1: Changes in fatigue severity score, measured by Fatigue Severity Scale (FSS) [ Time Frame: 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Scripps ResearchLa JollaCalifornia92037-

Find similar trials in La Jolla, CA

By condition
COVID-19 / long COVID
By specialty
Infectious disease
By research site
Scripps Research· La Jolla, CA

Related Studies